Table 1 SNPs highly associated with melanoma risk in sex-stratified analysis

AP3B1

rs11742673

5

A

0.0020

1.43 (1.14–1.80)

0.88

0.98 (0.75–1.28)

0.0210

CDK2/SILV

rs2069398

12

A

3.03E−4

0.47 (0.31–0.71)

0.06

0.60 (0.35–1.03)

0.0016

F2RL1

rs2242991

5

G

0.56

0.92 (0.68–1.22)

0.0076

1.61 (1.13–2.29)

0.0067

GPR143

rs2521667

X

G

0.46

0.89 (0.67–1.20)

7.04E−4

1.89 (1.30–2.74)

7.85E−4

rs2732872

X

C

0.78

0.96 (0.73–1.27)

8.43E−4

1.81 (1.27–2.57)

0.0052

KIT

rs6554198

4

G

0.46

0.92 (0.73–1.15)

0.0027

0.67 (0.51–0.87)

0.07

MYO7A

rs3758708

11

A

0.20

1.30 (0.87–1.95)

4.12E−4

2.38 (1.46–3.90)

0.0480

RAB38

rs524121

11

C

0.0086

0.51 (0.30–0.85)

0.36

1.32 (0.73–2.38)

0.0210

RGS20

rs6981243

8

C

0.38

0.90 (0.71–1.14)

0.0021

0.66 (0.51–0.86)

0.0490

SLC45A2

rs35414

5

T

0.03

0.77 (0.61–0.97)

0.0018

0.66 (0.51–0.85)

0.39

rs35415

5

A

0.03

0.78 (0.62–0.97)

0.0080

0.70 (0.54–0.91)

0.35

TYR

rs1042602

11

A

0.35

1.11 (0.89–1.40)

0.0047

0.68 (0.53–0.89)

0.0081

rs12270717

11

C

0.60

1.07 (0.82–1.40)

0.0032

1.56 (1.16–2.09)

0.09

rs17793678

11

T

0.32

1.14 (0.88–1.49)

0.0036

1.55 (1.15–2.08)

0.26

rs2186640

11

G

0.39

0.90 (0.71–1.15)

9.20E−4

1.57 (1.20–2.05)

0.0380

rs5021654

11

C

0.47

0.92 (0.72–1.16)

2.03E−4

1.66 (1.27–2.17)

0.0014